Wada T, Kanagawa R, Ishimura Y, Inada Y, Nishikawa K
Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, Osaka, Japan.
J Hypertens. 1995 Jan;13(1):113-22.
To study the effects of blockade of the renin-angiotensin system on the development of hypertension and end-organ damage in hyporeninaemic deoxycorticosterone acetate (DOCA)-salt hypertensive rats, using an angiotensin II (Ang II) receptor antagonist (TCV-116) or an angiotensin converting enzyme (ACE) inhibitor (enalapril).
DOCA-salt hypertensive rats were produced by uninephrectomy, implantation with DOCA pellets and 1% NaCl loading. TCV-116 (0.1 or 1 mg/kg) or enalapril (10 mg/kg) was given orally once a day from 3 to 6 weeks after the operation. Body weight, blood pressure, plasma renin and creatinine, urinary protein and blood urea nitrogen were measured. After 3 weeks' treatment, oedema and omega 3-subtype benzodiazepine receptor binding in the brain were measured.
Three weeks after the operation the blood pressure in the DOCA-salt hypertensive rats was approximately 200 mmHg, and the plasma renin concentration was lower than in sham-operated rats. However, after a further 3 weeks the renin concentration was slightly above the normal level, and this increase was accompanied by a decrease in body weight and increases in blood urea nitrogen, plasma creatinine, urinary protein and omega 3-subtype benzodiazepine receptor binding in the cerebral cortex, and by brain oedema. Treatment with TCV-116 or enalapril prevented renal damage and decrease in body weight with little effect on blood pressure. Enalapril prevented brain oedema and the increase in benzodiazepine binding in the brain cortex, and 1 mg/kg TCV-116 prevented them markedly.
Although the hypertension in DOCA-salt hypertensive rats is independent of the renin-angiotensin system, the degree of cerebral and renal damage is associated with the activity of the renin-angiotensin system and has little relationship with the blood pressure level.
使用血管紧张素II(Ang II)受体拮抗剂(TCV - 116)或血管紧张素转换酶(ACE)抑制剂(依那普利),研究肾素 - 血管紧张素系统阻断对低肾素性醋酸脱氧皮质酮(DOCA)-盐高血压大鼠高血压发展及靶器官损害的影响。
通过单侧肾切除术、植入DOCA微丸和给予1%氯化钠负荷来制备DOCA -盐高血压大鼠。术后3至6周,每天口服一次TCV - 116(0.1或1 mg/kg)或依那普利(10 mg/kg)。测量体重、血压、血浆肾素和肌酐、尿蛋白以及血尿素氮。治疗3周后,测量脑内水肿和ω3亚型苯二氮䓬受体结合情况。
术后3周,DOCA -盐高血压大鼠的血压约为200 mmHg,血浆肾素浓度低于假手术大鼠。然而,再过3周后,肾素浓度略高于正常水平,且这种升高伴随着体重下降、血尿素氮、血浆肌酐、尿蛋白增加以及大脑皮质中ω3亚型苯二氮䓬受体结合增加,同时伴有脑水肿。用TCV - 116或依那普利治疗可预防肾损害和体重下降,对血压影响较小。依那普利可预防脑水肿和大脑皮质中苯二氮䓬结合增加,1 mg/kg TCV - 116可显著预防这些情况。
尽管DOCA -盐高血压大鼠的高血压与肾素 - 血管紧张素系统无关,但脑和肾损害程度与肾素 - 血管紧张素系统的活性相关,与血压水平关系不大。